Day: December 1, 2025

HONG KONG, Dec. 01, 2025 (GLOBE NEWSWIRE) — Intercont (Cayman) Limited (Nasdaq: NCT) (“NCT” or “the Company”), a global carbon-neutral shipping company, announced that its Singapore subsidiary, Openwindow, has entered into a strategic partnership with CINCO INTERNATIONAL HONGKONG LIMITED. The partnership is designed to deliver stable, multi-year cash flow while expanding NCT’s shipping segment with assets that meet the industry’s accelerating shift toward low-carbon operations. CINCO INTERNATIONAL HONGKONG LIMITED is a well-established ro-ro shipping company known for its operational excellence and professional service standards. This partnership reflects NCT’s strategic initiative to expand its shipping segment in response to rising market demand. Ro-ro vessels are purpose-built for transporting automobiles and wheeled cargo,...

Company moved from Expert Market to OTCQB, restored SEC reporting, continues to grow revenue and builds Keen Labs platform in fast-growing battery and energy storage markets MARLBOROUGH, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) — ConnectM Technology Solutions, Inc. (OTC: CNTM) (“ConnectM” or the “Company”), a constellation of technology-driven businesses powering the modern energy economy, today provides an update on its capital markets turnaround since its Nasdaq delisting in May 2025 and announces that it has engaged ThinkEquity LLC as its investment bank to advise on an anticipated uplisting to a major U.S. exchange. Management believes investor appetite for companies enabling AI hyperscalers, battery power, energy storage and backup power solutions remains strong and that its Keen Labs subsidiary gives ConnectM focused exposure...

MELBOURNE, Australia, Dec. 01, 2025 (GLOBE NEWSWIRE) — Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel treatments for recurrent and metastatic cancer, today announced that it has submitted a request for a foreign filing license from Spain for two provisional patents detailing new methods to treat resistant cancer and fibrosis. The patents will be filed with IP Australia under Propanc Pty Ltd, the Company’s wholly owned operating subsidiary based in Melbourne, Australia. These discoveries stem from Propanc’s Joint Research and Drug Discovery program with the Universities of Jaén and Granada in Spain and are expected to be filed subsequently in key global jurisdictions. The first provisional patent covers methods for treating cancers that have developed resistance...

Steve Gutterman to Serve as CEO; Sim Salzman to serve as CFO WEST PALM BEACH, Fla., Dec. 01, 2025 (GLOBE NEWSWIRE) — Yorkville Acquisition Corp. (Nasdaq: MCGA), a special purpose acquisition company (the “SPAC”) sponsored by Yorkville Acquisition Sponsor LLC, announced today the appointments of public company veterans, Steve Gutterman as CEO and Sim Salzman as CFO in connection with the closing of the proposed business combination (the “Business Combination”). The Business Combination will result in the founding partners of Trump Media Group CRO Strategy, Inc., which include Trump Media & Technology Group (Nasdaq: DJT) and Crypto.com, contributing assets to establish a digital asset treasury company focused on acquisition of the native cryptocurrency token of the Cronos ecosystem (“CRO”). “CRO is a high-performance token,...

WOODCLIFF LAKE, N.J., Dec. 01, 2025 (GLOBE NEWSWIRE) — Hudson Technologies, Inc. (NASDAQ: HDSN) announced that its board of directors has approved an increase to the Company’s share repurchase authorization. Hudson may now purchase up to $20 million in shares of its common stock during calendar year 2025, an increase from up to $10 million of outstanding common stock previously authorized for 2025. Furthermore, the board of directors authorized the Company to repurchase up to $20 million of outstanding common stock in calendar year 2026. Under the share repurchase program, Hudson may purchase shares of its common stock on a discretionary basis from time to time through open market repurchases or through other means, including by entering into Rule 10b5-1 trading plans, in each case, during an “open window” and when the Company...

BOCA RATON, FL, Dec. 01, 2025 (GLOBE NEWSWIRE) — DeFi Development Corp. (Nasdaq: DFDV) (the “Company”), the first public company with a treasury strategy built to accumulate and compound Solana (“SOL”), today announced it has begun integrating and running the open block-building infrastructure provided by Harmonic across its Solana validator operations. Harmonic introduces competition and choice into Solana’s block-building pipeline. Instead of relying on a single builder, validators can select from multiple block candidates each slot. This improves revenue potential, strengthens decentralization, and gives operators more control over the types of order flow they accept. For DFDV, integrating Harmonic provides three clear benefits:Higher validator revenue: Harmonic allows DFDV to automatically choose the most valuable block each...

VANCOUVER, Washington, Dec. 01, 2025 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including metastatic triple-negative breast cancer (mTNBC) and colorectal cancer (mCRC), today announced that it has reached an agreement in principle to resolve the previously disclosed securities class action lawsuit that was initially filed in March 2021 against the Company and certain former officers. The case is pending in the United States District Court for the Western District of Washington and is titled Courter et al. v. CytoDyn Inc. et al. The parties reached an agreement in principle to resolve the...

Submission of NDA in South Korea by Lotus Pharmaceutical results in the second ex-U.S. regulatory submission for VIZZ SAN DIEGO and TAIPEI, Taiwan, Dec. 01, 2025 (GLOBE NEWSWIRE) — LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Lotus Pharmaceutical Co., Ltd. (“Lotus”, TWSW Stock Code: 1795) today announced that Lotus has submitted a New Drug Application (NDA) to the Ministry of Food and Drug Safety (MFDS) for the review and approval of VIZZTM, for the treatment of presbyopia in adults in South Korea. This represents the first submission for approval under the exclusive license and commercialization agreement signed in May 2025 for South Korea and certain countries in Southeast Asia. The NDA submission was supported by positive data from three randomized, double-masked, controlled Phase 3 studies (CLARITY trials) conducted in the United...

MOUNTAIN VIEW, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) — RenovoRx, Inc. (Nasdaq: RNXT) (“RenovoRx” or “the Company”), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, today announced that Chief Executive Officer Shaun Bagai will present at the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025, held on December 9-10, 2025. Mr. Bagai’s presentation will be held on Tuesday, December 9th at 12:30 P.M. ET. Mr. Bagai will share updates on RenovoRx’s continued commercial efforts and market traction, underscored by growing clinical demand and adoption of RenovoCath as a standalone, targeted drug-delivery device across both new and repeat customers. RenovoRx recently reported third quarter of 2025 financial results, demonstrating...

Milestone enables immediate production of SiN/PEEK custom devices SALT LAKE CITY, Utah, Dec. 01, 2025 (GLOBE NEWSWIRE) — SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics and biomaterials company, today announced that it has signed a supply agreement with Evonik Corporation (“EVONIK”), a global leader in high‑performance polymers, to manufacture the Company’s proprietary silicon nitride–PEEK compound (SiN/PEEK) (U.S. Patent No. 10,806,831) engineered for AI‑assisted additive manufacturing of patient‑specific implants that will be produced using equipment already in place at SINTX’s U.S.-based production facility. Under the agreement, EVONIK will produce SiN/PEEK compound leveraging its commercial-scale capability to SINTX’s specifications, enabling the Company to immediately begin manufacturing...